Equities

PureTech Health PLC

PRTC:LSE

PureTech Health PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)126.60
  • Today's Change-1.60 / -1.25%
  • Shares traded687.28k
  • 1 Year change-13.99%
  • Beta1.4686
Data delayed at least 20 minutes, as of Feb 06 2026 16:56 GMT.
More ▼

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year PureTech Health PLC grew revenues 44.98% from 3.33m to 4.83m while net income improved from a loss of 65.70m to a gain of 53.51m.
Gross margin--
Net profit margin498.87%
Operating margin549.01%
Return on assets5.63%
Return on equity14.65%
Return on investment6.57%
More ▼

Cash flow in USDView more

In 2024, PureTech Health PLC increased its cash reserves by 46.87%, or 89.56m. Cash Flow from Investing totalled 240.89m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 134.37m for operations while cash used for financing totalled 16.96m.
Cash flow per share0.1083
Price/Cash flow per share11.86
Book value per share1.16
Tangible book value per share1.16
More ▼

Balance sheet in USDView more

PureTech Health PLC appears to have a strong balance sheet and has grown its cash reserves consistently over the last four years to total 280.64m. In fact, 0.91% of the value of PureTech Health PLC shares can be attributed to this cash.
Current ratio8.49
Quick ratio--
Total debt/total equity0.0556
Total debt/total capital0.0537
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items increased 187.90%. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
EPS growth(5 years)-32.06
EPS (TTM) vs
TTM 1 year ago		168.33
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.